lendingclub corpor lc buy pt guidanc mostli consensu due announc bank acquisit
lower pt maintain buy acquisit promis analyst michael diana full summari
appl inc hold expect china demand shift due coronaviru though lack channel
otter tail corpor buy pt reduc estim lower manufactur plastic ep maintain buy
pt util dividend growth analyst tate sullivan cfa full summari
corp ai hold new asset alloc strategi could possibl increas coi cover dividend
maintain hold wait-and-se analyst michael diana full summari
bellerophon inc blph buy pt hemodynam data deliv de-risk reiter buy
immutep limit immp buy pt valuat rise first catalyst deliv lung cancer
 breast cancer analyst jason mccarthi ph full summari
brainstorm cell inc bcli buy pt al trial track multipl sclerosi trial continu
corpor event pleas contact maxim salesperson inform
concierg technolog inc cncg ndr nyc david neibert wed-thu feb
envis solar intern inc evsi cover sullivan ndr nyc ceo desmond wheatley wed feb
chesapeak util cover sullivan ndr boston cfo beth cooper treasur thoma mahn
envis solar intern inc evsi cover sullivan ndr chicago ceo desmond wheatley wed
graham corpor cover sullivan ndr nyc cfo jeffrey glajch tue
otter tail corpor cover sullivan ndr nyc ceo chuck macfarlan cfo kevin moug
super micro comput inc smci cover chokshi ndr nyc cfo kevin bauer wed
alarm com cover chokshi ndr philadelphia baltimor cfo steve valenzuela thu
pure storag inc cover chokshi ndr nyc cfo kevan chrysler thu apr
pure storag inc cover chokshi ndr boston cfo kevan chrysler fri apr
maxim group senior enterpris consum technolog analyst market boston chokshi mon apr
nutanix inc cover chokshi group lunch boston cfo duston tue apr
inc ndr boston cfo golder tue
guidanc mostli consensu due announc
bank acquisit lower pt maintain buy
result miss revenu ep beat adjust ebitda
guidanc consensu revenu adjust ebitda
high-end ep guidanc rang
importantli lc announc acquisit on-line bank radiu bank
privat manag expect transform combin close
month pay within two year thereaft see
prepar acquisit lc need build infrastructur custom
engag mainli guidanc expect
lower estim lower price target base
new estim
maintain buy rate believ acquisit show promis
could drive impress earn growth
consensu estim guidanc
adjust ebitda beat consensu
estim high-end guidanc ep
consensu match estim low-
end guidanc regard result solid reflect lc
emphasi effici profit growth
newli introduc guidanc includ total net revenu
midpoint consensu adjust ebitda
midpoint consensu ep consensu
toward high-end rang
acquisit radiu bank acquisit elimin fee paid third-parti
bank make lc-facilit loan lower fund cost enabl lc hold
loan balanc sheet accord manag equat annual
pre-tax benefit assum loan held on-bal sheet lc
pay stock bv ltm ni figur
acquisit pay within two year close view buy radiu
make sens start de novo bank
lower estim total net revenu estim
adjust ebitda estim
ep estim also introduc estim
importantli adjust ebitda estim
page updat earn model estim reflect
transit year includ contribut radiu bank
lower price target lc share current trade ev/
ebitda multipl price target lc ev/ebitda multipl
would previous repres premium valuat
best-compar ondeck hold believ lc trade materi
premium ondeck lc take direct credit risk wherea ondeck
lc grow ebitda much faster ondeck estim vs
adjust ebitda growth lc vs neg growth ondeck
reiter buy rate reiter buy rate due belief acquisit
radiu bank could drive impress earn growth next four quarter
expect stock price appreci price target
click full note
expect china demand shift due
coronaviru though lack channel data leav
statement lead us expect china demand shift
due coronaviru though lack channel data leav uncertainti
statement lead us expect china demand shift
due coronaviru though lack channel data leav uncertainti monday
even announc guidanc withdrawn due
impact coronaviru epidem suppli demand note prior revenu
guidanc repres acceler y/i growth
dec assum would result fulfil demand
excess suppli airpod base limit nyc store
check believ strong airpod demand rel suppli persist
take reason assert face valu demand region
greater china revenu in-lin expect
presum origin guidanc base addit make assumpt
disrupt suppli notabl iphon cite exceed disrupt
demand given presenc channel inventori factori re-start
albeit slower pace expect reflect origin guidanc
provid assumpt shift demand
expect greater china jun dec
across iphon ipad home/wearables/oth see estim revis grid
page net result shift
dec assumpt demand push back premis
gener held investor view user stay user becam
difficult analyt support elimin disclos unit channel data
began decemb
maintain hold rate maintain hold rate gross profit oper profit
remain rel flattish level sinc gross profit
oper profit share current trade ntm ep believ
investor like alreadi embed close attach rate iphon
user refresh cycl correspond watch asp airpod
asp well high paid attach rate tv well
multipl util across coverag univers
click full note
hemodynam data deliv de-risk
blph share high intra-day yesterday
announc posit top-lin data hemodynam studi
inopuls pulmonari hypertension-associ pulmonari fibrosi
improv hemodynam paramet pulmonari vascular
resist reduct mean pulmonari arteri pressur
reduct new safeti signal
measur gold standard pulmonari hypertens trial
set data also demonstr dose-depend effect
import valid data trial recal patient
fail basic everi vasodil use inopuls significantli improv
vascular resist correl signific improv
mvpa moder vigor physic activ measur includ
patient report outcom bottom line de-risk program
hemodynam data- result acut hemodynam studi
valid long-term cohort data on-going studi
demonstr clinic meaning improv multipl pre-specifi
pulmonari hemodynam paramet studi start ino dose
escal pulmonari vascular resist reduc
increas benefit dose compar mean
pulmonari arteri pressur also reduc import take-away
set data valid data measur chronic aspect
diseas set data also valid dose-depend inopuls effect
also import combin data de-risk upcom pivot trial
initi
inopuls phase cohort data- recal cohort report
evalu ino mcg/kg ibw/hr week cohort evalu
mcg/kg ibw/hr week cohort met primari endpoint
studi howev posit result cohort enhanc cohort
set stage move pivot trial primari endpoint mvpa
improv cohort cohort respect import
note function placebo deterior patient drug cohort
remain stabl goal wider delta cohort driven
cohort sicker patient deterior bit rapidli focu
patient drug remain stabl data mvpa cohort show valu
cohort improv patient longer
treatment period mvpa pe pivot trial overal activ improv
cohort respect dispar relat placebo deterior
differ bottom line patient drug deterior much
longer period time cohort week vs week patient report outcom
also posit cohort st georg respiratori questionnair sgrq
score activ impact univers california san diego short
breath questionnair move like cohort week
drug even though show sign deterior due inopuls
howev longer treatment period week higher dose cohort move
needl significantli improv point activ impact
short breath respect
click full note
valuat rise first catalyst deliv
lung cancer breast cancer
yesterday immutep presented/report posit data all-com pd-
trial part german cancer congress
berlin immp share februari expect build around
shown lung cancer data data first catalyst
disappoint said valuat still
upsid immp share view next key catalyst approach
phase data aipac breast cancer trial trial could
potenti serv file registr eu
signific data event immutep
takeaway import note signific lung cancer data
respons rate albeit rel small popul orr
wherea keytruda monotherapi orr
express addit respons regardless pd-
express view critic lower express least like
respond keytruda
rise nois checkpoint combin essenti everywher
hundr trial keytruda lung cancer respons rate
data rise nois level space view
unlock valu investor
beast cancer data next aipac trial breast cancer space
discuss
phase collabor merck nr suppli agreement
evalu efti combin pembro multicent open-label studi two
cancer type describ enrol across site us eu
australia
primari endpoint phase studi object respons
rate orr accord irecist secondari endpoint includ safeti
toler combo respons rate accord irecist diseas control rate
dcr progress free surviv overal surviv os pharmacokinet
immunogen profil efti
part initi data part lung cancer pdx naiv posit
first patient enrol cohort overal respons rate
orr achiev interim analysi septemb
increas note patient enrol regardless statu
data compar respons rate seen keytruda monotherapi patient
high express typic respons rate seen low expressor
consider lower follow posit result first interim
analysi part expand allow recruit addit patient
cohort total part recruit cohort part
on-going present enrol major patient still
treatment median yet continu pg
click full note
continu enrol
yesterday morn brainstrom report result net loss
compani current cash balanc sheet
exclud cirm iia grant remain
focu remain complet trial nurown al recal
trial fulli enrol readout expect later
phase trial multipl sclerosi ms enrol patient
plan februari studi patient receiv three intrathec
inject nurown msc-ntf cell week interim data expect
continu watch activ around al space pick-up particularli
around healey al platform trial see prior note link mass gener
key site nurown
nurown repres uniqu approach al treatment amyotroph later
sclerosi al lead degener motor neuron locat brain
spinal cord common form progress motor neuron diseas
motor neuron link central nervou system brain spinal cord
voluntari muscl respons speak walk breath swallow gener
movement bodi result motor neuron deterior commun
muscl impair result gradual weaken develop fascicul
twitch eventu atrophi wast away muscl signal impuls
nurown believ act reestablish nerve-muscl commun
induct new neuron growth repair existing/damag
neurotroph factor deriv patient bone marrow induc secret
larg amount neurotroph factor inject back patient
exampl msc-ntf includ glial deriv neurotroph factor gdnf brain
deriv neurotroph factor bdnf vascular endotheli growth factor vegf
hepatocyt growth factor hgf induct augment ntf secret relat
cell grown cultur coach combin cell
autolog start safeti issu
al trial prior data suffic bla submiss brainstorm recent
met fda confirm approv pathway nurown al phase trial
well prior data suffici bla submiss al phase trial
fulli enrol patient track report data later trial
evalu dose nurown cell made use singl harvest due
brainstorm cryopreserv platform dose week follow-
month first dose month primari endpoint includ
al function rate scale alsfrsr respond analysi pivot data expect
month last patient treat
nurown ms phase trial phase trial enrol patient
progress ms interim data expect studi patient
receiv three intrathec inject msc-ntf cell autolog mesenchym stem
cell cultur genet modifi increas express secret
neuron growth factor week follow addit week
primari endpoint safeti secondari endpoint includ time walk
speed test chang baselin particip express neurotroph factor
click full note
reduc estim lower manufactur plastic
ep maintain buy pt util dividend
reduc ep
follow result y/i growth non-util ep
ep equal forecast consensu ep
guidanc forecast current
consensu three analyst cover
y/i growth manufactur plastic busi
indic flat-to-low incom non-util busi
result off-set util growth less non-util
incom forecast
maintain buy rate base outlook dividend growth
util incom continu grow due multipl invest project
announc increas dividend current
forecast previous approv util spend project help
off-set lower ep near-term non-util busi achiev
annual ep growth rate target
decreas estim base flat non-util incom
guidanc report yesterday even ep rose y/i driven
y/i increas util ep reduct corpor cost tax rate
non-util ep howev unchang prior year
expect lower revenu manufactur busi recreat vehicl
custom plastic anticip lower sale price result
consider forecast non-util ep declin
y/i
util growth help achiev target long-term annual ep growth
believ util project help increas util busi
earn driven futur incom util project well incom
allow fund use construct afudc expect util ep
growth growth util ep growth offset
declin non-util ep forecast dividend pay-out ratio declin
target pay-out ratio
lower estim still expect ep growth long-term
ep growth target confer call includ first time
present indic expect long-term ep growth rate
although decreas ep note still forecast
ep growth long-term target
maintain buy rate price target current pe multipl
base ep forecast averag forward pe multipl
util peer group price target base ep
estim previous base price target
prior ep estim appli slightli higher pe multipl
compar peer group averag pe base higher rate
util ep growth result current invest project includ wind farm
natur ga power plant specif forecast util ep growth increas
addit note
announc increas dividend current yield
compani overview busi mix includ electr util
ep forecast plastic manufactur util distribut
electr custom minnesota north dakota south dakota separ
industri custom outsourc manufactur work also sell
click full note
cover dividend maintain hold wait-and-se
ai report core oper incom coi versu
dividend book valu mainli due invest gain
ai new strategi alloc capit mortgag credit asset
higher return could possibl increas core oper incom cover
dividend estim reflect
ai current trade discount book valu per share
also trade discount mortgag reit similar recent
oper histori maintain hold rate wait
see new asset alloc strategi success
oper incom versu quarterli dividend ep
due invest gain book valu per share
oper incom ep exclud invest gain loss
includ tba dollar-rol incom period cost interest rate swap regard
better measur econom incom ep therefor
estim non-gaap ep
coverag dividend second consecut quarter ai core oper incom
versu quarterli dividend shortfal due
part ai agenc portfolio lower yield lower leverag therefor
absenc strategi chang much higher leverag possibl
view ai would cut dividend capit alloc
higher-return mortgag credit asset manag indic capit
alloc could doubl possibl core oper incom could increas cover
dividend estim reflect
maintain dividend estim unchang current
quarterli dividend core oper incom non-gaap ep estim
cover dividend also introduc estim dividend
cover core oper incom page updat earn model
note dividend estim equat yield
maintain hold maintain hold rate wait see new asset
alloc strategi success
click full note
maxim analyst coverag univers
sector coverag
care well
industri util
receiv full disclosur compani maxim group coverag mention report pleas send
